Acorai, a Helsingborg based medical device startup, has successfully closed an oversubscribed seed equity round, securing over €4.1 million ($4.5 million). This funding, along with a €2.3 million non-dilutive grant and a future €10 million equity financing from the European Innovation Council (EIC), will support clinical studies and regulatory approval efforts.

The investment round was led by Solardis Health Ventures and saw participation from several investors, including KHP Ventures and the Carma Fund.

“Raising capital in this environment is tougher than it was even 18 months ago, so it’s a huge achievement of the management team and an example of how truly scalable this platform could be in the right hands”

says Andrew J Sauer

“This funding further validates that Acorai is a uniquely positioned company to change the paradigm of how patients with heart failure are managed in traditional and acute care settings. To my knowledge, this is the only company that has recognized and is adequately addressing the glaringly obvious unmet need within the acute heart failure workflow,”

Andrew J Sauer continues

Acorai, recognized as a Breakthrough Device by the US FDA, is conducting the CAPTURE-HF global clinical study, focusing on a 1200-patient catheterization study, set to conclude in 2024. The Team, led by Filip Peters, Jakob Gelberg, Kasper Bourdette, and Matthew Mace, is planning the completion of their study in 2024, and through active engagement with regulators, Acorai is targeting US market access by 2025.